Kidney Panel Analysis Report

Nephrology — Renal Function & CKD Staging Assessment

Report ID: MAA-KID-D5F719
Generated: March 11, 2026
Analysis: AI-Powered Clinical Interpretation

Patient Profile

Sex / Age:
Male, 62 years
Height / Weight:
175 cm / 92 kg (BMI 30.0 — obese class I)
Reported symptoms:
Mild ankle swelling, increased nocturia (2–3× nightly), fatigue
Medical history:
Type 2 diabetes (12 years), hypertension (15 years), prior MI (2019)
Medications:
Metformin 1000 mg BID, lisinopril 20 mg, atorvastatin 40 mg, aspirin 81 mg

Summary Overview

Comprehensive renal function panel with electrolytes and urinalysis. 11 parameters analyzed; 4 outside reference range. Findings consistent with diabetic kidney disease, currently at CKD Stage G3a A2 per KDIGO classification.

11
Parameters
4
Out of Range
7
Within Range

KDIGO Staging & Calculated Indices

eGFR (CKD-EPI 2021):
52 mL/min/1.73m² → CKD G3a (mild–moderate decrease) [Inker LA, NEJM 2021]
Albumin/Creatinine Ratio:
178 mg/g → A2 (moderately increased albuminuria) [KDIGO 2012]
BUN/Creatinine ratio:
17:1 (within normal range; not suggestive of prerenal cause)
Anion gap:
11 mEq/L (normal)

Detailed Parameter Analysis

CreatinineOut of Range
Result
1.48 mg/dL
Reference (lab)
0.7–1.3 mg/dL
Trend
↑ from 1.21 (1y ago)
Mild elevation reflecting reduced renal filtration capacity. The 22% rise from 1.21 mg/dL one year ago indicates progressive disease rather than stable baseline. In the context of long-standing diabetes and hypertension, this trajectory is most consistent with diabetic kidney disease progression [KDIGO Diabetes Guidelines 2022].
eGFR (CKD-EPI 2021)Out of Range
Calculated
52 mL/min/1.73m²
Reference
≥90
CKD Stage
G3a
eGFR of 52 places this patient in CKD Stage G3a — mild-to-moderately decreased kidney function. At this stage, intervention significantly affects long-term trajectory; the focus shifts from screening to active progression-slowing therapy [KDIGO CKD 2012; Ronco C, Lancet 2017].
Urine Albumin/Creatinine RatioOut of Range
Result
178 mg/g
Reference
<30 mg/g
Albuminuria stage
A2 (moderate)
Moderately increased albuminuria (formerly "microalbuminuria"). This is a highly specific marker of glomerular endothelial injury in diabetes and an independent predictor of both cardiovascular and renal outcomes [Gerstein HC, JAMA 2001; KDIGO 2012]. Combined with reduced eGFR, classifies the patient as G3a A2 — moderate cardiovascular and renal risk.
Potassium (K+)Out of Range
Result
5.3 mEq/L
Reference (lab)
3.5–5.0 mEq/L
Severity
Mild hyperkalemia
Mild hyperkalemia, common at this CKD stage and amplified by ACE-inhibitor therapy (lisinopril). Not immediately concerning but warrants monitoring — potassium should be tracked when ACEi/ARB doses are titrated or dietary potassium changes [Palmer BF, NEJM 2004]. Cardiac risk increases above 5.5 mEq/L.

Differential Diagnosis — Conditions to Discuss with Your Physician

  • Diabetic Kidney Disease (DKD)High
    Long-standing T2DM (12 years), progressive eGFR decline, moderately increased albuminuria, concurrent retinopathy risk profile — classic biochemical signature of DKD [Alicic RZ, CJASN 2017]. Diagnosis is clinical; renal biopsy not routinely required when picture is consistent.
  • Hypertensive Nephrosclerosis (concurrent)High
    15 years of hypertension is independently sufficient to cause nephrosclerosis; almost always coexists with DKD in this patient profile. BP control targets per KDIGO ≤120/70 mmHg in proteinuric CKD [KDIGO Blood Pressure Guidelines 2021].
  • Atherosclerotic / Ischemic NephropathyModerate
    Prior MI and atorvastatin therapy raise probability of renovascular contribution. Renal artery stenosis would explain progressive course; consider renal Doppler if asymmetry of kidney size or refractory hypertension.
  • NSAID-induced injuryLow
    Daily aspirin 81 mg unlikely contributory at this dose; review history for occasional NSAID use which could be a modifiable factor.

Analytical Summary & Recommendations

Clinical pattern

The picture is dominated by diabetic kidney disease at CKD Stage G3a A2, with progressive trajectory over the past year. Mild hyperkalemia is iatrogenic-physiologic (ACEi + reduced GFR). Cardiovascular risk is elevated independently of renal outcome.

Recommended next investigations

  • Repeat creatinine, eGFR, ACR in 3 months to confirm CKD (KDIGO requires >3 months) [KDIGO 2012]
  • Comprehensive metabolic panel with phosphate, calcium, PTH (CKD bone-mineral assessment at G3a)
  • Renal ultrasound — assess kidney size, exclude obstruction, evaluate for asymmetry
  • HbA1c — current diabetes control directly affects renal trajectory
  • Lipid panel — cardiovascular risk co-management
  • Hemoglobin / iron studies — anemia screening (common at G3a+)

Disease-modifying interventions

  • Optimize ACEi/ARB: lisinopril 20 mg may need uptitration if BP >130/80; reduce or hold if K+ rises above 5.5 [KDIGO 2021]
  • SGLT2 inhibitor consideration: dapagliflozin/empagliflozin shown to slow CKD progression in DKD [Heerspink HJL, NEJM 2020 — DAPA-CKD; Perkovic V, NEJM 2019 — CREDENCE]
  • Tight BP control (target ≤130/80, ideally ≤120 systolic if tolerated)
  • Glycemic optimization (HbA1c target 7.0–7.5% — individualized) [ADA Standards of Care 2024]
  • Dietary potassium awareness — discuss high-K foods to moderate
  • Avoid nephrotoxins: NSAIDs, IV contrast where avoidable

Monitoring

  • eGFR + ACR every 3 months while in active management
  • Potassium recheck within 2 weeks of any ACEi/ARB dose change
  • Watch for: rapidly worsening edema, shortness of breath, decreased urine output, severe muscle weakness — escalate care immediately
⚠ Important
Stage G3a is the most actionable inflection point in CKD — interventions started here significantly delay or prevent progression to G4–G5 (dialysis-requiring disease). Schedule a structured review with your physician within 2–4 weeks.

Key Questions for Your Physician

  • Should I be started on an SGLT2 inhibitor given my CKD stage and diabetes?
  • Is my current BP target (and lisinopril dose) appropriate for my CKD stage?
  • What is my realistic HbA1c target given my age and comorbidities?
  • Should I be referred to a nephrologist now, or after the 3-month confirmatory labs?
  • Are there dietary changes (potassium, sodium, protein) I should adopt at this stage?
  • Should anemia and bone-mineral parameters be checked now or at next visit?

What This Means for You

Your kidneys are filtering at about 52% of normal capacity — this places you at CKD Stage 3a, which is the early-moderate range. The pattern strongly suggests that your long-standing diabetes and high blood pressure are slowly affecting kidney function, and the trend over the past year confirms slow progression.

This is not an emergency, but it is the most important point at which intervention makes a real difference. Stage 3a is when treatment can meaningfully slow or even halt further decline — that's why we want to act now rather than wait.

Three things will matter most: blood pressure control, blood sugar control, and likely adding a newer class of medication (SGLT2 inhibitor) which is shown to protect kidneys in your situation. The mild potassium elevation is something to keep an eye on but not a crisis.

Plan: schedule a focused review with your physician in the next 2–4 weeks, get the additional tests above, and discuss adding kidney-protective therapy. With consistent management, many patients with Stage 3a remain stable for many years.

Analysis Confidence 91%

High confidence: the clinical picture (long-standing T2DM + HTN), biochemistry (reduced eGFR, moderate albuminuria), and trajectory (1-year progression) form a coherent and well-recognized pattern. Confirmation of CKD requires the 3-month repeat per KDIGO criteria.

References

  1. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR Without Race. NEJM 2021;385(19):1737–49.
  2. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of CKD. Kidney Int Suppl 2013;3(1).
  3. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD. Kidney Int 2022;102(5S):S1–S127.
  4. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. CJASN 2017;12(12):2032–45.
  5. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. NEJM 2020;383(15):1436–46 (DAPA-CKD).
  6. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. NEJM 2019;380(24):2295–306 (CREDENCE).
  7. KDIGO 2021 Clinical Practice Guideline for Blood Pressure Management in CKD. Kidney Int 2021;99(3S):S1–S87.
  8. Palmer BF. Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System. NEJM 2004;351(6):585–92.